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derived from the treatment plan, geometric evaluation is typically in 
three orthogonal directions. The purpose of this study was to 
retrospectively evaluate the clinically applied compromises in terms 
of dose,using a dose estimation method that is fast enough to be used 
online. 
Materials and Methods: 15 NSCLC patients treated with SBRT (3 
fractions,54Gy), were selected where the classical geometric 
tolerance limits were exceeded during treatment and a compromise 
was made for the tumor alignment. 
A multiple local rigid registration method was implemented to 
estimate the patient deformation. 3D rectangular regions of 
interested (ROI) were used for the following structures: spinal cord, 
sternum, trachea, carina, heart and the OARs receiving a high dose, 
while the tumor was registered using a shaped region of interest. 
Thin-plate spline interpolation was used to calculate the deformation 
vector field, allowing a deformation of the planning CT delineations 
onto the CBCT image. Subsequently, the maximum dose was 
estimated (assuming local dose shift invariance) for the OAR, 
comparing the setup correction purely based on the tumor position 
and the clinical compromise. For the GTV the difference in D99 was 
calculated. 
Results: Results are summarized in table 1 for each fraction 
separately (44 in total). For only two thirds of the OARs a decrease of 
de max dose was achieved after compromise. For 6 out of 113 OARs (2 
patients), the max dose tolerance limit was exceeded without 
compromise (range 0.1 – 1.6 Gy), meaning that only for 2 out of 15 
patients a compromise was actually needed. After compromise 2 OARs 
out of 6 were still above their maximum dose tolerance limit (range 
0.1 – 0.2 Gy). For the tumor dose 44 GTVs were evaluated. In general, 
the compromise showed a decrease in D99 for the GTV. In one case, 
the decrease in tumor dose was extreme (almost 10 Gy), due to a 
compromise made to spare a nearby vessel. 
 
 
 
Conclusions: Even when geometrical constraints were exceeded, 
dosimetric evaluation showed that it was not necessary to perform a 
compromise between tumor and OAR registration in many cases. In 
addition, the geometric compromise was not always effective. 
Dosimetric tolerance limits and evaluations will therefore be more 
effective and efficient in compromising between tumor treatment and 
OAR sparing. 
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Purpose/Objective: Previous studies showed the feasibility to detect 
range uncertainties (>4 mm) of ion beams in the head and neck (H&N) 
with particle therapy (PT) PET, in an automated way. This study 
explores whether patient setup errors can be detected with PT-PET in 
an automated manner using an in-house developed software based on 
the Pearson's correlation coefficient (PCC-SW). 
Materials and Methods: Using standard planning CTs carbon-ion plans 
were made with TRiP98. From this treatment plans the reference PT-
PET β+-activity distribution was simulated using an in-house developed 
MC platform. In the next step the initial beam settings were applied 
on craniocaudal (cc) shifted CTs (2 to 6 mm) to simulate patient miss-
positioning. Then the expected β+-activity was calculated for each 
plan with shifts. Finally, the reference PT-PET images were compared 
to the 'shifted' β+-activity distribution simulations using the PCC-SW. 
Tumors in the H&N, prostate, lung and brain were investigated. To 
account for different monitoring scenarios the in-beam PET was 
compared to three different in-room scenarios, starting the PET 
measurement 1-2 min after the end of irradiation and lasting for 3 to 
5 min.  
Results: The median tumor coverage dropped significantly in all 
indications by simulating a cc patient shift of 4 mm or more. The 
automated PCC evaluation of the PT-PET data showed that in 
inhomogeneous tissue (e.g. H&N) miss-positioning of 4 mm and more 
can be detected. Cc-shifted prostate PT-PET images were too similar 
to detect shifts in longitudinal direction. Regarding lung lesions the 
definiteness of detecting patients’ shifts depended strongly on the 
exact location of the tumor, i.e. detection possibility decreased for 
lesions in close vicinity to the thoracic wall. By evaluating several PT-
PET scenarios the absolute difference of the PCC to the PCC of the 
initial β+-activity distribution was largest for an in-room scenario with 
up to 2 minutes delay between irradiation and measurement 
(measurement time > 300s).  
Conclusions: The evaluation of various indices that describe 
treatment plan quality after different miss-positioning scenarios 
showed once more the essential need of a particle beam monitoring 
system. The automated evaluation of PT-PET images depends strongly 
if the enclosed tissue is homogeneous or not. A large tumor size was 
found to be an additional challenge for PT-PET. However, the PCC 
based automated method is a quick and useful technique to support 
human decisions in the clinical routine. The exploration of different 
monitoring scenarios indicates a recommendation towards a full-ring 
PET scanner right next to the treatment site. The evaluation of set-up 
uncertainties will be extended to anterior-posterior and rotational 
shifts of the patient.  
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Purpose/Objective: Accuracy has been compared between 3D and 4D 
CBCT based lung tumor registrations. 
Materials and Methods: An Elekta Synergy with x-ray volume imaging 
functionality (XVI system) was used in this study. Twenty lung cancer 
patients were selected, and single-arc volumetric modulated arc 
therapy (VMAT) was applied for stereotactic body radiotherapy (SBRT) 
under constrained breathing condition induced by abdominal 
compression plate. Planning CT data and contours of internal tumor 
volume (ITV) and other risk organs were transferred from treatment 
planning system to the XVI unit. Three-dimensional (3D) CBCT 
registration was performed for 10 patients, and 4D CBCT registration 
was performed for the remaining 10 patients. For both cases, kV 
projection images were acquired during VMAT delivery, and in-
treatment four-phase 4D CBCT was reconstructed by in-house 
software in each of four fractions thereby providing moving tumor 
locations along with imported ITV contours on the XVI display. As a 
registration accuracy measure, an over-travel distance of the moving 
tumor from the contoured ITV surface was defined, and it was 
evaluated in the lateral, vertical, and longitudinal directions. Using 
this measure, we compared the registration accuracy between 3D and 
4D CBCT techniques. 
Results: In-treatment 4D CBCT for the 20 patients showed that the 
amplitude of tumor motion was always less than 10 mm in all 
directions. For the 3D CBCT based registration, the average over-
travel distances during treatment for the 10 patients were 0.41 ± 0.93 
(standard deviation), 0.17 ± 0.58, and 0.62 ± 0.99 mm for the CC, LR, 
and AP directions, respectively. The over-travel distances in each of 
four breathing phases did not exceed 5 mm in any directions. For the 
4D CBCT registration, the average over-travel distances during 
treatment for the 10 patients were 0.32 ± 0.56, 0.18 ± 0.43, and 0.28 
± 0.53 mm for the CC, LR, and AP directions, respectively. The over-
travel distances in each of four phases did not exceed 3 mm in any 
directions. Figure 1 compares histograms of observed over-travel 
distances between 3D CBCT and 4D CBCT based registrations, where 
the over-travel distance was counted for each of the four phases in 
each patient. 
 
